H3041

Halopemide

≥98% (HPLC)

• Sinónimos: N-(2-(4-(5-Chloro-2-oxo-1-benzimidazolinyl)piperidino)ethyl)-p-fluorobenzamide
• Fórmula empírica (notación de Hill): C₂₁H₂₂ClFN₄O₂
• Número CAS: 59831-65-1
• Peso molecular: 416.88
• NACRES: NA.77
• PubChem Substance ID: 329815189
• UNSPSC Code: 12352204
• MDL number: MFCD00866684
• Assay: ≥98% (HPLC)
• Form: powder

Propiedades

• assay: ≥98% (HPLC)
• form: powder
• color: off-white
• solubility: DMSO: >10 mg/mL
• storage temp.: 2-8°C
• SMILES string: Fc1ccc(cc1)C(=O)NCCN2CCC(CC2)N3C(=O)Nc4cc(Cl)ccc34
• InChI: 1S/C21H22ClFN4O2/c22-15-3-6-19-18(13-15)25-21(29)27(19)17-7-10-26(11-8-17)12-9-24-20(28)14-1-4-16(23)5-2-14/h1-6,13,17H,7-12H2,(H,24,28)(H,25,29)
• InChI key: NBHPRWLFLUBAIE-UHFFFAOYSA-N

Descripción

Application

Halopemide, a non-specific phospholipase D (PLD) antagonist, may be used with selective PLD antagonists (CAY10593, a PLD1 antagonist; CAY10594 or ML298, selective PLD2 antagonist) to help define the role and physiological effects regulated by phospholipase D enzymes. Halopemide may be used as the basis of the design and development of more selective PLD antagonists.[1][2]

Biochem/physiol Actions

Halopemide is a dopamine receptor antagonist and a phospholipase D2 inhibitor.

Halopemide is a dopamine receptor antagonist and a phospholipase D2 inhibitor. Halopemide may be used as a screen to identify inhibitors of human PLD2 using an in vitro biochemical assay. It is also inhibitory at benzodiazepine binding sites.

Información de seguridad

• pictograms: GHS07
• signalword: Warning
• hcodes: H302
• pcodes: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable